# Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.

> **NCT07633613** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Centre Antoine Lacassagne** · enrollment: 110 (estimated)

## Conditions studied

- Non-Small Cell Lung Carcinoma (NSCLC)
- Metastatic Head and Neck Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Blood sampling
- **PROCEDURE:** Tumor biopsies for biobank establishment (optional)

## Key facts

- **NCT ID:** NCT07633613
- **Lead sponsor:** Centre Antoine Lacassagne
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2029-05
- **Final completion:** 2029-05
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07633613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07633613, "Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07633613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*